Abstract:To elucidate the antileukemi effects of berbamine and the possible molecular mechanisms in vitro and in vivo, MTT method was used to examine the effect of berbamine on K562 cell growth. The apoptosis rate was measured by flow cytometry. The mRNA expression level of BCR/ABL gene (semiquantity value) was determined by RT-PCR and the BCR/ABL protein (P210) level was detected by Western blot. The K562-bearing mice were used to reveal the therapeutic effect in vivo. The results showed that a significant time- and concentration-dependent inhibition of cell growth was found in the cells treated with berbamine. After the cells were exposed to 8.0 microg/ml berbamine for 24, 48 and 72 hours, the percentage of growth inhibition of K562 cells progressively increased by (26.63 +/- 3.57)%, (61.84 +/- 4.74)%, (75.32 +/- 1.95)%, respectively (compared with control, P < 0.01). The IC(50) (72 hours) value was 5.227 +/- 1.307 microg/ml. The apoptosis rate of K562 cells treated with 8.0 microg/ml berbamine for 24 and 72 hours increased from (29.20 +/- 3.82)% to (61.77 +/- 4.35)% (P < 0.01). Berbamine down-regulated the expression levels of bcr/abl gene and P210 in K562 cells in a time- and concentration-dependent manner. The bcr/abl expression decreased from (1.38 +/- 0.02) to (0.97 +/- 0.01) after exposure of the cells to 8.0 microg/ml berbamine for 0 and 72 hours (P < 0.01). When the cells were treated with 4.0 - 16.0 microg/ml berbamine for 24 hours, the level of P210 decreased from (0.95 +/- 0.03) to (0.63 +/- 0.01) (P < 0.01). In vivo, after treatment for 4 weeks, the tumor weight of berbamine-treated group was also lower than that of untreated group [(1.46 +/- 0.43) g vs (2.90 +/- 0.94) g, P < 0.01] and the inhibition rate was 49.66%, moreover, berbamine down-regulated the expression level of bcr/abl gene of tumor cells. It is concluded that berbamine can obviously inhibit the cell proliferation and induce apoptosis in K562 cell lines in a time- and concentration-dependent manner in vitro. The mechanisms of berbamine-induced apoptosis may be involved in down-regulation of bcr/abl gene expression and P210 level. In vivo, berbamine can aslo display a better antileukemic effect and down-regulate expression of bcr/abl gene. Berbamine extracted from Chinese herb may be a promising candidate of new drug for clinical anticancer treatment, especially for bcr-abl(+) diseases.

[Effects of Proteasome Inhibitor Bortezomib on NF-kappaB Activity and ICAM-1 Mrna Expression of K562 Cells].

Study on Effects of Bortezomib on Expression of ICAM-1 of K562 Cells

Overcoming Acquired TRAIL Resistance in Human Colon Cancer by Proteasome Inhibitor Bortezomib

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

Study on the effects of proteasome inhibitor PS-341 on apoptosis and expression of cytokines of U266 cells

[Apoptosis in Jurkat Cells Induced by Bortezomib Combined with Adriamycin].

[Effects of Berbamine on K562 Cells and Its Mechanisms in Vitro and in Vivo].

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

Effects of Different Concentrations of Bortezomib on the Expression of NF-κB, IκB and P-gp of DNR-resistant K562 Cells

Molecular Mechanisms of Converting K562/DNR Cellular Drug-Resistance by Bortezomib.

Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.

Inhibitory Effect of 4-Chlorobenzoyl Berbamine on Imatinib-Resistant K562 Cells in Vitro and in Vivo

Effect of Bortezomib on Global Gene Expression in PC12-Derived Nerve Cells

Bik/NBK Accumulation Correlates with Apoptosis-Induction by Bortezomib (PS-341, Velcade) and Other Proteasome Inhibitors

[Effect of Bortezomib on MAPK Signaling Pathway of K562/DNR Cells].

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Synergistic Effect of HMGB1 Knockdown and Cordycepin in the K562 Human Chronic Myeloid Leukemia Cell Line.

[Effect of Bortezomib on Sensitization of HL-60 Cells to TRAIL].

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Berbamine, a Novel Nuclear Factor Κb Inhibitor, Inhibits Growth and Induces Apoptosis in Human Myeloma Cells

Effects of Berbamine on Growth of Leukemia Cell Line NB4 and Its Mechanism